Microsatellite Instability Clinical Trials

11 recruitingLast updated: May 13, 2026

There are 11 actively recruiting microsatellite instability clinical trials across 5 countries. Studies span Phase 2, Phase 1, Phase 3. Top locations include Guangzhou, Guangdong, China, Pittsburgh, Pennsylvania, United States, Dijon, France. Updated daily from ClinicalTrials.gov.


Microsatellite Instability Trials at a Glance

11 actively recruiting trials for microsatellite instability are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Guangzhou, Pittsburgh, and Dijon. Lead sponsors running microsatellite instability studies include Sun Yat-sen University, Dan Zandberg, and Centre Hospitalier Universitaire Dijon.

Browse microsatellite instability trials by phase

Treatments under study

About Microsatellite Instability Clinical Trials

Looking for clinical trials for Microsatellite Instability? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Microsatellite Instability trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Microsatellite Instability clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1Phase 2

FOG-001 in Locally Advanced or Metastatic Solid Tumors

Colorectal, CancerProstate CancerCancer+12 more
Parabilis Medicines, Inc.595 enrolled29 locationsNCT05919264
Recruiting
Phase 1

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Amgen464 enrolled8 locationsNCT07403721
Recruiting
Phase 2

Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies

Hepatocellular CarcinomaMelanomaEsophageal Adenocarcinoma+5 more
Dan Zandberg72 enrolled1 locationNCT04114136
Recruiting
Phase 1Phase 2

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Colorectal, CancerEsophageal CancerGastric Cancer+18 more
Neonc Technologies, Inc.134 enrolled6 locationsNCT06047379
Recruiting
Phase 2

Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer

Colorectal, CancerNeoadjuvant TherapyMismatch Repair-deficient (dMMR)+1 more
Sun Yat-sen University270 enrolled1 locationNCT03926338
Recruiting

Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Metastatic Colorectal Cancer (CORESIM)

Colorectal Cancer MetastaticMicrosatellite Instability-High Colorectal Cancer
Federation Francophone de Cancerologie Digestive600 enrolled20 locationsNCT06353854
Recruiting
Phase 2

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Colorectal, CancerPancreatic CancerGastric Cancer+7 more
Udai Kammula240 enrolled1 locationNCT03935893
Recruiting
Phase 3

Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO

Triple-Negative Breast CancerCervical CancerUrothelial Carcinoma+12 more
UNICANCER646 enrolled40 locationsNCT05078047
Recruiting
Phase 1Phase 2

Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer

Colorectal Cancer Stage IVMismatch Repair-deficient (dMMR)Microsatellite Instability-high (MSI-H)
Sun Yat-sen University28 enrolled1 locationNCT05426005
Recruiting
Phase 3

PRODIGE 90 - (FFCD 2204) Neoadjuvant Dostarlimab with Short Course Radiotherapy in a Watch-and-wait Strategy for Microsatellite Unstable or Mismatch Repair-deficient Locally Advanced Rectal Cancer Patients

Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
Centre Hospitalier Universitaire Dijon68 enrolled1 locationNCT06762405
Recruiting
Phase 3

Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer

Colorectal, CancerMicrosatellite Instability High
Sun Yat-sen University180 enrolled1 locationNCT06520683